Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions;Utilidad de los stents recubiertos de rapamicina en pacientes diabéticos con lesiones coronarias complejas

Revista Espanola de Cardiologia

Volumn 59, Issue 2, 2006, Pages 117-124

  Berenguer Jofresa, Alberto ^a,b   Mainar, Vicente ^a   Bordes, Pascual ^a   Valencia, José ^a   Gómez, Silvia ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE   (Spain)

Author keywords

Angioplasty; Diabetes; Drug eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RAPAMYCIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; SEX; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33645579003     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084638     Document Type: Article

References (26)

1. Mak KH, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J. 2003;24:1087-103.
2. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, et al, for the Intermountain Heart Collaborative Study (IHCS). Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351-8.
3. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584-9.
4. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43:8-14.
5. Hasdai B, Rizza RA, Grill DE, Scott CG, Garratt KN, Holmes DR. Glycemic control and outcome of diabetic patients after successful percutanous coronary revascularization. Am Heart J. 2001;141:117-23.
6. Hill RA, Dündar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J. 2004;25:902-19.
7. Colombo A, Iakovou I. Drug-eluting stents: the new gold standard for percutaneous coronary revascularization. Eur Heart J. 2004;25:895-7.
8. Moussa I, Leon MB, Baim DS, O'Neil WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. A SIRIUS (sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-8.
9. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. on behalf of the RAVEL Invesigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J. 2004;25:107-12.
10. Sarembock I. Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus. Curr Diab Rep. 2004;4:13-9.
11. Scheen AJ, Warzée F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care. 2004; 27:1840-1.
12. Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002;45:1475-83.
13. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase and MAP-kinase mediated signalling in human muscle. J Clin Invest. 2000;105:311-20.
14. Berg CE, Lavan BE, Rondinone CM. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun. 2002;293:1021-7.
15. Berenguer A, Mainar V, Bordes P, Valencia J, Gómez S, Lozano T. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high risk patients. Am Heart J. 2005;150: 536-42.
16. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000;36:355-65.
17. Mathew V, Gersh BJ, Williams A, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109:476-80.
18. Lemos PA, Serruys PW, Van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the «real world». Circulation. 2004;109:190-5.
19. Radke PW, Kobella S, Kaiser A, Franke A, Schuber D, Grube E, et al. Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy. Eur Heart J. 2004;25:920-5.
20. Shawhney N, Moses JW, Leon MB, Kuntz RE, Popma JJ, Bachinsky W, et al. Treatment of left anterior descending coronary artery with sirolimus eluting stents. Circulation. 2004;110:374-9.
21. Arampatzis CA, Lemos PA, Hoye A, Saia F, Tanabe K, Van der Giessen WJ, et al. Elective sirolimus-eluting stent implantation or left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv. 2004;62:292-6.
22. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughessy C, Mann JT, et al for the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent. The TAXUS-IV trial. Circulation. 2004;109: 1942-7.
23. Schofer J, Schülter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol. 2000;35:1554-9.
24. Huber K. The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics. J Thromb Thrombolysis. 2003;15:99-103.
25. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolín R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-eluting stent (DIABETES) trial. Circulation. 2005; 112:2175-83.
26. Lázaro P. Stents recubiertos de fármacos: eficacia, efectividad, eficiencia y evidencia. Rev Esp Cardiol. 2004;57:608-12.